08:00 , Feb 14, 2011 |  BioCentury  |  Strategy

Alexion's expansions

Alexion Pharmaceuticals Inc. last week laid out its plans for keeping up the momentum that has resulted in a doubling of market cap in the past year, from $4.1 billion on Feb. 12, 2010, to...
07:00 , Oct 6, 2008 |  BC Week In Review  |  Clinical News

Taligen Therapeutics preclinical data

TT32 reduced airway hyperresponsiveness (AHR) and eosinophilic airway inflammation in mice challenged with ovalbumin. The compound also attenuated goblet cell hyperplasia and TH2 cytokine production. TT32 is a complement alternative pathway inhibitor composed of a...
07:00 , Oct 6, 2008 |  BC Week In Review  |  Clinical News

Taligen Therapeutics preclinical data

In a mouse heterotopic heart transplant model, TT32 protected grafts from ischemia reperfusion injury (IRI) as assessed by histology, C3 deposition, and a reduction in neutrophils and inflammatory cytokines. Multiple doses of TT32 improved graft...